Real-world effectiveness and safety of oral anticoagulation strategies in atrial fibrillation: a cohort study based on a German claims dataset

References

• Gomez-OutesASuarez-GeaMLDiscovery of anticoagulant drugs: a historical perspectiveCurr Drug Discov Technol201298310421838662
   PubMedGoogle Scholar
• ElgendyAYMahttaDBarakatAFMeta-analysis of safety and efficacy of uninterrupted non-vitamin K antagonist oral anticoagulants versus vitamin K antagonists for catheter ablation of atrial fibrillationAm J Cardiol20171201830183628882334
   PubMed Web of Science ®Google Scholar
• DentaliFRivaNCrowtherMTurpieAGGLipGYHAgenoWEfficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literatureCirculation20121262381239123071159
   PubMed Web of Science ®Google Scholar
• MillerCSGrandiSMShimonyAFilionKBEisenbergMJMeta-analysis of efficacy and safety of new oral anticoagulants (Dabigatran, Rivaroxaban, Apixaban) versus Warfarin in patients with atrial fibrillationAm J Cardiol201211045346022537354
   PubMed Web of Science ®Google Scholar
• RuffCTGiuglianoRPBraunwaldEComparison of the efficacy and safety of new oral anticoagulants with Warfarin in patients with atrial fibrillation: a meta-analysis of randomised trialsLancet201438395596224315724
   PubMed Web of Science ®Google Scholar
• OgilvieIMNewtonNWelnerSACowellWLipGYHUnderuse of oral anticoagulants in atrial fibrillation: a systematic reviewAm J Med201012363820609686
   PubMed Web of Science ®Google Scholar
• Gomez-OutesATerleira-FernandezAICalvo-RojasGSuarez-GeaMLVargas-CastrillonEDabigatran, Rivaroxaban, or Apixaban versus Warfarin in patients with nonvalvular atrial fibrillation: a systematic review and meta-analysis of subgroupsThrombosis2013201364072324455237
   PubMedGoogle Scholar
• ConnollySJEzekowitzMDYusufSEikelboomJRE-LY Steering Committee and InvestigatorsDabigatran versus Warfarin in patients with atrial fibrillationN Engl J Med20093611139115119717844
   PubMed Web of Science ®Google Scholar
• PatelMRMahaffeyKWGargJROCKET AF InvestigatorsRivaroxaban versus Warfarin in nonvalvular atrial fibrillationN Engl J Med201136588389121830957
   PubMed Web of Science ®Google Scholar
• MekajYHMekajAYDuciSBMiftariEINew oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic eventsTher Clin Risk Manag20151196797726150723
   PubMed Web of Science ®Google Scholar
• BauerKAPros and cons of new oral anticoagulantsHematology Am Soc Hematol Educ Program2013201346447024319220
   PubMed Web of Science ®Google Scholar
• AbrahamNSSinghSAlexanderGCComparative risk of gastrointestinal bleeding with Dabigatran, Rivaroxaban, and Warfarin: population based cohort studyBMJ2015350h185725910928
   PubMed Web of Science ®Google Scholar
• MauraGBlotièreP-OBouillonKComparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with Dabigatran or Rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort studyCirculation20151321252126026199338
   PubMed Web of Science ®Google Scholar
• GrahamDJReichmanMEWerneckeMCardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with Dabigatran or Warfarin for nonvalvular atrial fibrillationCirculation201513115716425359164
   PubMed Web of Science ®Google Scholar
• GrangerCBAlexanderJHMcMurrayJJApixaban versus Warfarin in patients with atrial fibrillationN Engl J Med201136598199221870978
   PubMed Web of Science ®Google Scholar
• LalibertéFCloutierMNelsonWWReal-world comparative effectiveness and safety of Rivaroxaban and Warfarin in nonvalvular atrial fibrillation patientsCurr Med Res Opin2014301317132524650301
   PubMed Web of Science ®Google Scholar
• BancroftTLimJWangCSanderSDSwindleJPHealth care resource utilization, costs, and persistence in patients newly diagnosed as having nonvalvular atrial fibrillation and newly treated with Dabigatran versus Warfarin in the United StatesClin Ther201638354556e1626856927
   PubMed Web of Science ®Google Scholar
• PicciniJPHellkampASLokhnyginaYRelationship between time in therapeutic range and comparative treatment effect of Rivaroxaban and Warfarin: results from the ROCKET AF TrialJ Am Heart Assoc20143e000521e00052124755148
   PubMed Web of Science ®Google Scholar
• FrickeUGüntherJZawinellAAnatomisch-therapeutisch-chemische Klassifikation mit Tagesdosen für den deutschen Arzneimittelmarkt: Methodik der ATC-Klassifikation und DDD-Festlegung; ATC-Index mit DDD-Angaben. [Anatomical Therapeutic Chemical Classification with daily doses for the German pharmaceutical market: Methodology of the ATC classification and DDD definition; ATC Index with DDD information]WIdO2004 German
   Google Scholar
• WHO Collaborating Centre for Drug Statistics MethodologyGuidelines for ATC classification and DDD assignment 2017Oslo2016 [cited December 19, 2017]. Available from: https://www.whocc.no/filearchive/publications/2017_guidelines_web.pdfAccessed December 19, 2017
   Google Scholar
• Jaspers FocksJBrouwerMAWojdylaDMPolypharmacy and effects of Apixaban versus Warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trialBMJ2016353i286827306620
   PubMed Web of Science ®Google Scholar
• GrahamDJReichmanMEWerneckeMStroke, bleeding, and mortality risks in elderly Medicare beneficiaries treated with Dabigatran or Rivaroxaban for nonvalvular atrial fibrillationJAMA Intern Med20161761662167127695821
   PubMed Web of Science ®Google Scholar
• Al-KhaliliFLindstromCBensonLThe safety and persistence of non-vitamin-K-antagonist oral anticoagulants in atrial fibrillation patients treated in a well structured atrial fibrillation clinicCurr Med Res Opin201632417
   Web of Science ®Google Scholar
• WilkeTGrothAFuchsAPfannkucheMMaywaldUPersistence with VKA treatment in newly treated atrial fibrillation patients: an analysis based on a large sample of 38,076 German patientsEur J Clin Pharmacol201773111437144728780697
   PubMed Web of Science ®Google Scholar
• PokorneySDO’BrienECGrangerCBAssessing generalizability of trial results in general practiceEur Heart J2016371154115726516173
   PubMed Web of Science ®Google Scholar
• BeinemaMBrouwersJacobusRBJSchalekampTWilffertBPharmacogenetic differences between Warfarin, acenocoumarol and phenprocoumonThromb Haemost20081001052105719132230
   PubMed Web of Science ®Google Scholar
• MichalskiFTittlLWerthSSelection, management, and outcome of vitamin K antagonist-treated patients with atrial fibrillation not switched to novel oral anticoagulants. Results from the Dresden NOAC registryThromb Haemost20151141076108425994496
   PubMed Web of Science ®Google Scholar
• ConnollySJPogueJEikelboomJBenefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic rangeCirculation20081182029203718955670
   PubMed Web of Science ®Google Scholar
• WallentinLLopesRDHannaMEfficacy and safety of Apixaban compared with Warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillationCirculation20131272166217623640971
   PubMed Web of Science ®Google Scholar
• MuellerSPfannkucheMBreithardtGThe quality of oral anti-coagulation in general practice in patients with atrial fibrillationEur J Intern Med20142524725424477050
   PubMed Web of Science ®Google Scholar